Patent intelligence · US
US 11364261
Alleviating common cold and influenza symptoms with molecular hydrogen
Alleviating common cold and influenza symptoms with molecular hydrogen
Patent details — US 11364261
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 21, 2022
- Expiration
- Jun 16, 2042
- Applicant
- H2 Universe LLC
- Claims
- 11
- CPC classes
- A61K, A61K33/06, A61K47/02, A61K47/10
Quick answer
US 11364261 (Alleviating common cold and influenza symptoms with molecular hydrogen) is held by H2 Universe LLC. Status: granted. Granted Jun 21, 2022. Expires Jun 16, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- H2 Universe LLC
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K33/06, A61K47/02, A61K47/10, A61K47/26, A61K9/2009
More from H2 Universe LLC
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11364261?
US 11364261 (Alleviating common cold and influenza symptoms with molecular hydrogen) is held by H2 Universe LLC. Status: granted. Granted Jun 21, 2022. Expires Jun 16, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11364261?
H2 Universe LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 11364261 expire?
Our index shows an expiration date of Jun 16, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.